A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years
10.3760/cma.j.issn.1003-9279.2011.05.021
- VernacularTitle:阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者4年疗效观察
- Author:
Jia-Yi LIAN
1
;
Xiao-An YANG
;
Ka ZHANG
;
Lu-Biao CHEN
;
Xin SHU
;
Qi-Huan XU
Author Information
1. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
- Keywords:
Hepatitis B,chronic;
Nucleotides;
Adefovir;
Hepatitis B e antigens
- From:
Chinese Journal of Experimental and Clinical Virology
2011;25(5):384-386
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years.Methods Ninety-five patients with HBeAg-positive chronic hepatitis B were treated with adefovir dipivoxil 10 mg per day orally.The patients were observed before and after treatment for their serum levels of ALT and HBV DNA,the new increasing rates of serum ALT normalization,HBV DNA clearances,HBeAg loss,HBeAg seroconversion and adverse drug events.Results At 4 years on study,the rates of ALT normalization,HBV DNA clearances,HBeAg loss,HBeAg seroconversion and HBV DNA rebound were 89.5％,63.2％,47.4％,41.1％ and 8.0％,respectively.No drug related to renal function impairment was found during the treatment,eight patients had adverse drug events but all were mild.Conclusion Adefovir dipivoxil could effectively inhibit HBV replication,normalize ALT and enhance transformation from HBeAg to HBeAb for cases with naive and treated-first patients.The efficacy were increased with prolongation of the treatment period.It is safe and has a good tolerance.
